GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Accumulated other comprehensive income (loss)

Larimar Therapeutics (STU:ZA71) Accumulated other comprehensive income (loss) : €0.05 Mil (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Larimar Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was €0.05 Mil.

Larimar Therapeutics's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2024 (€0.32 Mil) to Dec. 2024 (€0.14 Mil) and declined from Dec. 2024 (€0.14 Mil) to Mar. 2025 (€0.05 Mil).

Larimar Therapeutics's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 (€-0.03 Mil) to Dec. 2023 (€0.07 Mil) and increased from Dec. 2023 (€0.07 Mil) to Dec. 2024 (€0.14 Mil).

Larimar Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Larimar Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Accumulated other comprehensive income (loss) Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial - - -0.03 0.07 0.14

Larimar Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.14 0.32 0.14 0.05

Larimar Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Larimar Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
VTYX TARA NKTR LCTX SGMO LYEL HURA SEER ALEC NKTX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
LRMR:USA
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Website
https://www.larimartx.com
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines